Related Experiment Video
Updated: Aug 6, 2026

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight
Tapan A Patel1, Jill Rose1, Kenichi Katsurada2,3
1Department of Cellular and Integrative Physiology (T.A.P., J.R., P.K., J.S., K.P.P., M.A.), University of Nebraska Medical Center, Omaha.
Abstract:
GLP-1R (glucagon-like peptide-1 receptor) agonists are transforming therapeutic strategies in hypertension and cardiometabolic syndrome by shifting the focus from merely controlling individual risk factors to modifying the vascular-metabolic biology that underpins these conditions. In addition to promoting weight loss and improved glycemic control, growing clinical and experimental evidence indicates their beneficial effects on endothelial dysfunction, vascular inflammation, leukocyte recruitment, atherosclerotic plaque composition, and cardiorenal pathways involved in sodium regulation and neurohumoral balance, key processes in cardiometabolic-related hypertension and associated heart failure. This review integrates rapid clinical advancements in GLP-1R agonists with emerging mechanistic insights, clarifying which findings are well-established and which remain inferential, and identifying significant translational gaps that would provide deeper insight into cardiometabolic diseases. Key priorities include determining which benefits reflect direct GLP-1R signaling within cardiovascular/renal tissues versus secondary cardiometabolic changes, establishing cell type-resolved GLP-1R localization in human heart and kidney, and developing response biomarkers for cardiovascular and heart failure outcomes. Addressing these issues through detailed trial phenotyping, advanced mechanistic imaging, and relevant experimental models will facilitate personalized application of existing therapies and inform the development of next-generation incretin-based strategies aimed at durable vascular protection and blood pressure regulation for better cardiovascular health.
More Related Videos
08:21Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
Published on: June 28, 2019
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
G-protein Coupled Receptors
GPCRs Regulate Adenylyl Cylase Activity
Two...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.